ESG

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

As EVgo nears breakeven, it brings in a seasoned financial architect from the energy sector to steer its capital-intensive buildout toward profitability.

By replacing spreadsheets with a cloud platform, New Mexico created a 4.25x funding multiplier, setting a new standard for government efficiency.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

How Circus SE's autonomous robot is set to revolutionize corporate dining, tackling food waste and augmenting the workforce at a top auto plant.

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

Estonia's top utility secures key financing for a massive infrastructure upgrade. We decode the risks, rewards, and long-term impact for investors.

A Belgian med-tech firm is replacing a centuries-old procedure with an implantable pump, targeting a growing multi-billion dollar liver disease market.

BW LPG declared a solid dividend, yet its stock fell. We dissect the numbers, peer strategies, and market forces to see what this reveals about the shipping giant.

A new solar-plus-storage project in Sicily showcases how tailored energy solutions can boost industrial autonomy, cut costs, and withstand harsh climates.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Beyond the awards, the 2025 TISDC reveals Taiwan's strategy for global creative leadership and how young designers are tackling the world's biggest problems.

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.